US20120093914A1 - Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration - Google Patents

Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration Download PDF

Info

Publication number
US20120093914A1
US20120093914A1 US13/130,969 US200913130969A US2012093914A1 US 20120093914 A1 US20120093914 A1 US 20120093914A1 US 200913130969 A US200913130969 A US 200913130969A US 2012093914 A1 US2012093914 A1 US 2012093914A1
Authority
US
United States
Prior art keywords
matrix
liposomes
cells
cell
canceled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/130,969
Other languages
English (en)
Inventor
Shai Yehoshua Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moma Therapeutics
Original Assignee
Moma Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moma Therapeutics filed Critical Moma Therapeutics
Priority to US13/130,969 priority Critical patent/US20120093914A1/en
Assigned to SCHUBERT HOLDINGS LLC reassignment SCHUBERT HOLDINGS LLC PURCHASE AGREEMENT Assignors: MOMA THERAPEUTICS, INC.
Publication of US20120093914A1 publication Critical patent/US20120093914A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/222—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/438—Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626—Liposomes, micelles, vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Definitions

  • the PCL particles are embedded within a hydrogel matrix such as collagen or hyaluronic acid that help hold the particles in place following their delivery in the body.
  • a hydrogel matrix such as collagen or hyaluronic acid that help hold the particles in place following their delivery in the body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/130,969 2008-11-24 2009-11-24 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration Abandoned US20120093914A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/130,969 US20120093914A1 (en) 2008-11-24 2009-11-24 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20021408P 2008-11-24 2008-11-24
US20021308P 2008-11-24 2008-11-24
US20020808P 2008-11-24 2008-11-24
US20020708P 2008-11-24 2008-11-24
US13/130,969 US20120093914A1 (en) 2008-11-24 2009-11-24 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
PCT/US2009/065797 WO2010060104A2 (fr) 2008-11-24 2009-11-24 Composition matricielle incorporée dans des liposomes implantables, ses utilisations et particules de polycaprolactone comme échafaudages pour la régénération tissulaire

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065797 A-371-Of-International WO2010060104A2 (fr) 2008-11-24 2009-11-24 Composition matricielle incorporée dans des liposomes implantables, ses utilisations et particules de polycaprolactone comme échafaudages pour la régénération tissulaire

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/531,340 Division US9889232B2 (en) 2008-11-24 2014-11-03 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration

Publications (1)

Publication Number Publication Date
US20120093914A1 true US20120093914A1 (en) 2012-04-19

Family

ID=42198860

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/130,969 Abandoned US20120093914A1 (en) 2008-11-24 2009-11-24 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
US14/531,340 Active US9889232B2 (en) 2008-11-24 2014-11-03 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/531,340 Active US9889232B2 (en) 2008-11-24 2014-11-03 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration

Country Status (5)

Country Link
US (2) US20120093914A1 (fr)
EP (1) EP2370112B1 (fr)
CA (1) CA2781591A1 (fr)
DK (1) DK2370112T3 (fr)
WO (1) WO2010060104A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151725A1 (fr) 2012-04-05 2013-10-10 The Regents Of The University Of California Cellules de sérums de régénération et cellules souches mésenchymateuses
WO2015136479A1 (fr) * 2014-03-12 2015-09-17 Glaxosmithkline Biologicals S.A. Compositions liposomales pour administration par voie muqueuse
US20170157048A1 (en) * 2014-06-04 2017-06-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10837018B2 (en) 2013-07-25 2020-11-17 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6876636B2 (en) 2002-07-09 2005-04-05 Qualcomm Inc. Method and system for a multicast service initiation in a communication system
WO2011078990A1 (fr) * 2009-12-14 2011-06-30 Benaroya Research Institute At Virginia Mason Hydrogels comprenant du hyaluronane et au moins un agent d'induction de lymphocytes t
ITMI20111009A1 (it) 2011-06-01 2012-12-02 Milano Politecnico Idrogeli di gelatina reticolata
TWI449546B (zh) * 2011-09-07 2014-08-21 Ind Tech Res Inst 應用於軟硬組織修復與再生之生醫材料
WO2014039012A1 (fr) * 2012-09-06 2014-03-13 Nanyang Technological University Systèmes d'administration de médicament à base d'acide hyaluronique
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
EP2918262B1 (fr) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction d'une tolérance spécifique à des antigènes par phagocytose périphérique
EP3095440B1 (fr) * 2015-05-19 2020-01-15 PLS-Design GmbH Immunothérapie spécifique d'un antigène à l'aide de liposomes de tolérance
WO2017197262A1 (fr) * 2016-05-12 2017-11-16 Insitu Biologics, Llc Véhicule d'administration biologique à base d'hydrogel
US20200230159A1 (en) * 2017-08-09 2020-07-23 The Regents Of The University Of Michigan Apoptosis-mimicking structures
CN107496348A (zh) * 2017-08-28 2017-12-22 天津昂赛细胞基因工程有限公司 一种用于组织损伤修复的水凝胶及制备方法
CN109337877B (zh) * 2018-10-31 2021-11-12 安徽农业大学 二氯苯酚降解酶TcpA及其编码基因与生产菌的应用
CN110327498B (zh) * 2019-04-15 2021-02-02 北京大学口腔医学院 一种基于脂质体的活性小分子控释方法及其应用
CN116603076B (zh) * 2023-07-13 2023-10-10 四川大学华西医院 一种具有超疏水性能的药物结构涂层及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051812A1 (en) * 1996-04-12 2002-05-02 Dicosmo Frank Drug delivery via therapeutic hydrogels
US20050069518A1 (en) * 2003-02-12 2005-03-31 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US20060228417A1 (en) * 2003-07-31 2006-10-12 Pascale Hubert Mucoadhesive composition comprising polyacrylate and chemoattractant
US20070148220A1 (en) * 2003-12-23 2007-06-28 Mueller Rolf Liposomes and liposomal compositions for vaccination and drug delivery
US20070224280A1 (en) * 2006-03-21 2007-09-27 Lillard James W Novel nanoparticles for delivery of active agents
US7427602B1 (en) * 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
US20110287086A1 (en) * 2008-11-13 2011-11-24 Grayburn Paul A Regeneration of Pancreatic Islets and Reversal of Diabetes by Islet Transcription Factor Genes Delivered in Vivo

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578914A (ja) 1991-09-13 1993-03-30 Unitika Ltd 微生物分解性ステープル・フアイバー
AU700903B2 (en) * 1994-10-12 1999-01-14 Focal, Inc. Targeted delivery via biodegradable polymers
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
WO2001054735A2 (fr) * 2000-01-28 2001-08-02 Orthogene, Inc. Eponges a base de collagene destinees a la reparation et a l'augmentation tissulaire
WO2001087314A1 (fr) * 2000-05-18 2001-11-22 Genetix Pharmaceuticals, Inc. Procedes et compositions destines a promouvoir l'angiogenese au moyen de monocytes
AU2002343475A1 (en) * 2001-10-03 2003-04-14 Selective Genetics, Inc. Traversal of nucleic acid molecules through a fluid space and expression in repair cells
US20040132679A1 (en) * 2002-09-03 2004-07-08 Baylor College Of Medicine Induction of pancreatic islet formation
US20060140914A1 (en) * 2002-10-31 2006-06-29 The General Hospital Corporation Repairing or replacing tissues or organs
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20050186240A1 (en) * 2004-02-23 2005-08-25 Ringeisen Timothy A. Gel suitable for implantation and delivery system
WO2006069344A2 (fr) * 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Hydrogels a liberation regulee
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051812A1 (en) * 1996-04-12 2002-05-02 Dicosmo Frank Drug delivery via therapeutic hydrogels
US6475516B2 (en) * 1996-04-12 2002-11-05 Dicosmo Frank Drug delivery via therapeutic hydrogels
US7427602B1 (en) * 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
US20050069518A1 (en) * 2003-02-12 2005-03-31 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US20060228417A1 (en) * 2003-07-31 2006-10-12 Pascale Hubert Mucoadhesive composition comprising polyacrylate and chemoattractant
US20070148220A1 (en) * 2003-12-23 2007-06-28 Mueller Rolf Liposomes and liposomal compositions for vaccination and drug delivery
US20070224280A1 (en) * 2006-03-21 2007-09-27 Lillard James W Novel nanoparticles for delivery of active agents
US20110287086A1 (en) * 2008-11-13 2011-11-24 Grayburn Paul A Regeneration of Pancreatic Islets and Reversal of Diabetes by Islet Transcription Factor Genes Delivered in Vivo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ruel-Gariepy et al. Thermosensitive Chitosan-based Hydrogel Containing Liposomes for the delivery of Hydrophilic Molecules. Journal of Controlled Release, 2002. pages 373-383 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151725A1 (fr) 2012-04-05 2013-10-10 The Regents Of The University Of California Cellules de sérums de régénération et cellules souches mésenchymateuses
US10837018B2 (en) 2013-07-25 2020-11-17 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015136479A1 (fr) * 2014-03-12 2015-09-17 Glaxosmithkline Biologicals S.A. Compositions liposomales pour administration par voie muqueuse
BE1022346B1 (fr) * 2014-03-12 2016-03-25 Glaxosmithkline Biologicals S.A. Compositions liposomales pour une administration mucosale
US20170157048A1 (en) * 2014-06-04 2017-06-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10434064B2 (en) * 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11123294B2 (en) * 2014-06-04 2021-09-21 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11957788B2 (en) 2014-06-04 2024-04-16 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids

Also Published As

Publication number Publication date
DK2370112T3 (en) 2017-07-24
EP2370112A2 (fr) 2011-10-05
EP2370112B1 (fr) 2017-04-05
WO2010060104A3 (fr) 2010-10-28
WO2010060104A2 (fr) 2010-05-27
CA2781591A1 (fr) 2010-05-27
EP2370112A4 (fr) 2013-04-10
US9889232B2 (en) 2018-02-13
US20150050332A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
US9889232B2 (en) Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
JP7097629B2 (ja) 最小侵襲投与のための注射可能な予成形される肉眼的三次元スキャフォールド
US20220192986A1 (en) Injectable, pore-forming hydrogels for materials-based cell therapies
EP2370115B1 (fr) Eponges d'hydrogel, leurs procedes de production et leurs utilisation
Kim et al. Effect of pore structure of macroporous poly (lactide-co-glycolide) scaffolds on the in vivo enrichment of dendritic cells
Golchin et al. Combination therapy of stem cell-derived exosomes and biomaterials in the wound healing
CN109069875B (zh) 产生免疫耐受反应的组合物和方法
CN113518635A (zh) 用于调节免疫系统的生物工程化支架及其用途
CN108042793B (zh) 包埋gdnf的多核-单壳微球缓释系统的制备方法
Liu et al. Advances in hydrogels for stem cell therapy: regulation mechanisms and tissue engineering applications
US20210308334A1 (en) Oxygen-generating cryogels
Li et al. Concentrated conditioned medium-loaded silk nanofiber hydrogels with sustained release of bioactive factors to improve skin regeneration
WO2008121422A2 (fr) Composition de matrice de cellules implantable pour la délivrance de composés bioactifs
Umar Stem cell’s secretome delivery systems
Safina et al. Cell-Biomaterial constructs for wound healing and skin regeneration
Keshavarz et al. Using biomaterials to improve mesenchymal stem cell therapies for chronic, nonhealing wounds
Chen et al. Towards extracellular vesicle delivery systems for tissue regeneration: material design at the molecular level
Malafaya et al. Polymer based scaffolds and carriers for bioactive agents from different natural origin materials
Zhang et al. Mesenchymal stem cells-based drug delivery systems for diabetic foot ulcer: A review
Bhatta et al. Polymeric scaffolds for antitumor immune cell priming
Gaspar Novel strategy to produce a drug delivery system for skin regeneration
Zhang et al. WJD
Koshy Injectable Biomaterial Systems for Immuno-oncology

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHUBERT HOLDINGS LLC, MASSACHUSETTS

Free format text: PURCHASE AGREEMENT;ASSIGNOR:MOMA THERAPEUTICS, INC.;REEL/FRAME:026443/0221

Effective date: 20110601

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION